Literature DB >> 21669937

Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse.

C Papeix1, R Depaz, A Tourbah, B Stankoff, C Lubetzki.   

Abstract

We report the case of a young woman with multiple sclerosis who discontinued natalizumab twice and experienced a severe relapse following each natalizumab withdrawal. The first relapse was successfully treated by intravenous methylprednisolone (IVMP). In contrast the second relapse was unresponsive to IVMP. Subsequent treatment by plasma exchanges (PLEX) was followed by a dramatic neurological worsening. This case suggests that PLEX after natalizumab discontinuation may increase relapse severity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669937     DOI: 10.1177/1352458511411064

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  7 in total

Review 1.  Multiple sclerosis and pregnancy in the 'treatment era'.

Authors:  Sandra Vukusic; Romain Marignier
Journal:  Nat Rev Neurol       Date:  2015-04-21       Impact factor: 42.937

2.  Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

Authors:  Per Soelberg Sorensen; Nils Koch-Henriksen; Thor Petersen; Mads Ravnborg; Annette Oturai; Finn Sellebjerg
Journal:  J Neurol       Date:  2014-04-12       Impact factor: 4.849

Review 3.  Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Authors:  Joachim Havla; Ingo Kleiter; Tania Kümpfel
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423

4.  Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.

Authors:  Caroline Papeix; Sandra Vukusic; Romain Casey; Nadine Debard; Bruno Stankoff; Serge Mrejen; Zoe Uhry; Eric Van Ganse; Anne Castot; Michel Clanet; Catherine Lubetzki; Christian Confavreux
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-10-28

5.  Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient.

Authors:  Thomas H Massey; Rachel Smith; Shaheena Sadiq; Christopher Overton; Owen R Pearson
Journal:  Neurology       Date:  2017-01-11       Impact factor: 9.910

6.  Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.

Authors:  Inés González-Suarez; Luis Rodríguez de Antonio; Aida Orviz; Sara Moreno-García; María D Valle-Arcos; Jordi A Matias-Guiu; Cristina Valencia; Manuela Jorquera Moya; Celia Oreja-Guevara
Journal:  Brain Behav       Date:  2017-03-14       Impact factor: 2.708

7.  Aggressive multiple sclerosis (2): Treatment.

Authors:  Georgina Arrambide; Ellen Iacobaeus; Maria Pia Amato; Tobias Derfuss; Sandra Vukusic; Bernhard Hemmer; Lou Brundin; Mar Tintore
Journal:  Mult Scler       Date:  2020-06-12       Impact factor: 6.312

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.